RESUMEN
The COVID-19 global pandemic has devastated lives and economies. It has served as a reminder of how critical it is to invest in preventing and treating infectious diseases. Until the COVID-19 pandemic, the largest US government-sponsored reward for infectious disease drug and vaccine development was the Tropical Disease Priority Review Voucher program. Under this program, the Food and Drug Administration awards a priority review voucher to the sponsor of a new drug or vaccine for tropical infectious diseases. The voucher then can be exchanged for the faster review of one drug. We provide case studies for tropical disease voucher recipients between 2007 and 2018, examine the effects of the voucher program on product innovation and access, and recommend that policy makers protect the voucher program while creating complementary incentives.
Asunto(s)
COVID-19 , Pandemias , Desarrollo de Medicamentos , Humanos , SARS-CoV-2 , Estados Unidos , United States Food and Drug AdministrationRESUMEN
India and China have made major progress toward establishing research- and innovation-based health biotechnology sectors. Local health needs, including diseases that predominantly affect the poor, have driven much of this success. We argue that emerging domestic firms can play an important role as reliable and high-quality suppliers of existing products and as innovators for global health needs. Indeed, these firms' participation may make existing global health approaches more sustainable. However, global health stakeholders, including international donors and the Indian and Chinese governments, will need to fashion incentives for these companies to retain a strategic focus on the global poor.
Asunto(s)
Industria Farmacéutica/organización & administración , Salud Global , Biotecnología , China , Industria Farmacéutica/tendencias , IndiaRESUMEN
Gross inequities in disease burden between developed and developing countries are now the subject of intense global attention. Public and private donors have marshaled resources and created organizational structures to accelerate the development of new health products and to procure and distribute drugs and vaccines for the poor. Despite these encouraging efforts directed primarily from and funded by industrialized countries, sufficiency and sustainability remain enormous challenges because of the sheer magnitude of the problem. Here we highlight a complementary and increasingly important means to improve health equity: the growing ability of some developing countries to undertake health innovation.